These data further strengthen our confidence in Reblozyl’s potential to become a meaningful option for this important, underserved patient population around the world.â€... Jun 11
Bristol Myers Squibb today announced that its wholly-owned subsidiary, Celgene, and Cipla have settled their litigation related to patents for REVLIMID.... Dec 11
-Advertisements-